The Effects of Doxycycline on Reducing Symptoms in Knee Osteoarthritis: Results From a Triple-Blinded Randomized Controlled Trial. Snijders GF, van den Ende CH, van Riel PL, et al CONTEXTE: L'arthrose est une maladie articulaire chronique qui implique la dégénérescence du cartilage articulaire. Les données précliniques suggèrent que la doxycycline pourrait agir comme un agent modificateur de la maladie pour le traitement de l'arthrose, avec le potentiel de ralentir la dégénérescence du cartilage. Osteoarthritis is a chronic joint disease that involves degeneration of articular cartilage. Pre-clinical data suggest that doxycycline might act as a disease-modifying agent for the treatment of osteoarthritis, with the potential to slow cartilage degeneration. Abstract Background. Osteoarthritis is a chronic joint disease that involves degeneration of articular cartilage. Pre-clinical data suggest that doxycycline might act as a disease-modifying agent for the treatment of osteoarthritis, with the potential to slow cartilage degeneration. On the subject of doxycycline and osteoarthritis, rheumatologist Scott Zashin, M.D. commented, First of all, this is a unique study in that it was a relatively long-term study that looked at a medication to not only relieve pain, but also prevent progression of osteoarthritis of the knee. Twenty-five dogs were included in a randomized, double-blind trial to assess the efficacy of doxycycline (DOX) orally administered twice a day at 4 mg/kg/day (n = 12) for the treatment of osteoarthritis of the hip. Objective. To evaluate systemic inflammatory biomarkers in symptomatic knee osteoarthritis (OA) and their association with radiographic and biochemical OA progression. Preliminary evidence from experimental animal models has suggested that doxycycline may be effective in preventing or slowing the progression of osteoarthritis (OA), perhaps through its ability to modulate the activity of cartilage-degrading matrix metalloproteases (MMPs). Selection criteria: We included studies if they were randomised or quasi‐randomised controlled trials that compared doxycycline at any dosage and any formulation with placebo or no intervention in people with osteoarthritis of the knee or hip. Methods A 24-week, randomised, triple-blind, placebo controlled trial on the symptomatic effectiveness of doxycycline twice a day 100 mg in knee osteoarthritis patients according to the clinical and radiological American College of Rheumatology classification criteria.